April 28, 2014 / 10:11 AM / in 5 years

BRIEF-GSK, MMV start phase III programme to evaluate malaria drug Tafenoquine

April 28 (Reuters) - Glaxosmithkline Plc -

* GSK and Medicines for Malaria Venture (MMV) announce start of phase III programme of Tafenoquine for plasmodium vivax malaria

* Announced start of a phase III global programme to evaluate efficacy and safety of Tafenoquine

* Tafenoquine is not yet approved or licensed for use anywhere in world

* Phase III programme includes two randomised, double-blind treatment studies to investigate Tafenoquine in adult patients with p. vivax malaria Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below